Torsten Falk, PhD, University of Arizona, Tuscon, AZ, describes potential strategies to enable long-term use of levodopa in patients with Parkinson’s disease and levodopa-induced dyskinesia. Administration via an intestinal gel infusion using a percutaneous pump can provide more stable dopaminergic stimulation and initial studies have demonstrated the efficacy of low-dose ketamine to in patients with levodopa-induced dyskinesia. Additional dopamine receptor agonists are also needed to provide alternatives to levodopa. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr. Falk has a patent for the use of ketamine as a novel treatment for levodopa-induced dyskinesia associated with Parkinson’s disease, that has been licensed to PharmaTher Inc. in 2020. He also consulted for PharmaTher Inc., and received travel support.